THE EFFICACY OF ENZALUTAMIDE (ENZA) PLUS ANDROGEN DEPRIVATION THERAPY (ADT) ON OLIGOMETASTATIC HORMONE-SENSITIVE PROSTATE CANCER: EXTENDED POST HOC ANALYSIS OF ARCHES

DISEASE-FREE SURVIVAL WITH LONGER FOLLOW-UP FROM THE PHASE 3 CHECKMATE 274 TRIAL OF ADJUVANT NIVOLUMAB IN PATIENTS WHO UNDERWENT SURGERY FOR HIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMA

SAFETY, TOLERABILITY, AND EFFICACY OF TAR-200 IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO WERE UNFIT FOR CURATIVE INTENT THERAPY: A PHASE 1 TRIAL

ANTI-ADENOVIRUS ANTIBODY LEVELS PREDICT NADOFARAGENE FIRADENOVEC RESPONSE DURABILITY IN BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER: RESULTS FROM A PHASE 3 CLINICAL TRIAL

PATIENT-REPORTED SEXUAL AND URINARY FUNCTION IN NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER OR METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER FOLLOWING APALUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY IN SPARTAN AND TITAN

SAFTEY AND EFFICACY OF FIRST-IN-HUMAN PHASE I STUDY OF INTRAVESCIAL PEMBROLIZUMAB AND BCG IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER

CHANGES IN THE URINE IMMUNE MICROENVIRONMENT IN RESPONSE TO INTRAVESICAL PEMBROLIZUMAB AND BCG IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER

DIAGNOSTIC PERFORMANCE OF PIFLUFOLASTAT F 18-PET/CT IN MEN WITH BIOCHEMICAL RECURRENCE OF PROSTATE CANCER AFTER DEFINITIVE TREATMENT: A CONDOR STUDY SUBANALYSIS

PHASE 3 VERACITY CLINICAL STUDY OF SABIZABULIN IN MEN WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER WHO HAVE PROGRESSED ON AN ANDROGEN RECEPTOR TARGETING AGENT

SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF A NEOADJUVANT GEMCITABINE INTRAVESICAL DRUG DELIVERY SYSTEM (TAR-200) IN MUSCLE-INVASIVE BLADDER CANCER PATIENTS: A PHASE 1 TRIAL

THE OBESITY PARADOX IN PATIENTS WITH MUSCLE-INVASIVE UROTHELIAL BLADDER CANCER RECEIVING NEOADJUVANT IMMUNOTHERAPY

Preliminary results of a single arm Phase II trial of intraoperative intravesical Mitomycin C during Nephroureterectomy for Urothelial Carcinoma.

IMPACT OF 18F-FLUCICLOVINE PET/CT ON PLANS FOR ADT IN PATIENTS WITH BIOCHEMICAL RECURRENCE OF PROSTATE CANCER; DATA ANALYSIS FROM TWO PROSPECTIVE CLINICAL TRIALS

PHASE 1/2A TWO YEAR RECURRENCE FREE SURVIVAL AND MARKER LESION RESPONSE RATE FOR PROLIPOSOMAL PACLITAXEL (TSD-001) IN INTERMEDIATE RISK NMIBC

SWOG S1931 (PROBE): Phase III randomized trial of Immune checkpoint inhibitor (ICI) combination regimen with or without Cytoreductive Nephrectomy (CN) in Advanced Renal Cancer [NCT04510597]